(E)-3-<2-(metylpropionyloxy)phenyl>-2-propenoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-<2-(metylpropionyloxy)phenyl>-2-propenoic acid
• 英文别名: (E)-3-(2-(isobutyryloxy)phenyl)acrylic acid；(E)-3-[2-(2-methylpropanoyloxy)phenyl]prop-2-enoic acid
• 化学式: C₁₃H₁₄O₄
• 分子量: 234.252
• InChiKey: BJWSXMRHTCXISW-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  克他命 、 (E)-3-<2-(metylpropionyloxy)phenyl>-2-propenoic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以10%的产率得到(S,E)-2-(3-((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)amino)-3-oxoprop-1-en-1-yl)phenyl isobutyrate
  参考文献：
  名称：

  [EN] PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF
  [FR] PROMÉDICAMENTS À BASE DE KÉTAMINE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI

  摘要：

  提供了（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，其组成和用途。具有化学式（Ia）或（Ib）的化合物作为（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，以及包含本文提供的化合物的药物组合物用于治疗或预防中枢神经系统疾病。更具体地，相关疾病包括抑郁症和疼痛。（Ia）（Ib）

  公开号：

  WO2019137381A1
• 作为产物：
  描述：

  反式-2-羟基肉桂酸 、 异丁酸酐 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以98%的产率得到(E)-3-<2-(metylpropionyloxy)phenyl>-2-propenoic acid
  参考文献：
  名称：

  Two new improved approaches to the synthesis of coumarin-based prodrugs

  摘要：

  Our laboratory has recently reported the development of a coumarin-based, esterase-sensitive prodrug system for the preparation of prodrugs of amines, peptides, and peptidomimetics. Biological evaluations including animal studies have demonstrated me clinical potential of this prodrug system. However, the original synthetic method used required a long sequence of reactions with a relatively low overall yield. In this report, we describe two new approaches to the synthesis of these coumarin-based prodrugs. The first approach is a photochemical approach taking advantage of the photoisomerization of cinnamic acid and its derivatives. The second approach is through the catalytic hydrogenation of a triple bond for the generation of me cis double bond in the coumarinic acid moiety. Both approaches allow for the synthesis of these prodrugs in fewer steps with much improved overall yield. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00121-0

文献信息

• [EN] PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS À BASE DE KÉTAMINE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XW LAB INC

  公开号：WO2019137381A1

  公开（公告）日：2019-07-18

  Provided are prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine,composition and uses thereof. Compounds having formula (Ia) or (Ib) as the prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine, and pharmaceutical compositions comprising the compounds provided herein are used for treating or preventing a CNS disease.More particularly, the related diseases include depression and pain. (Ia) (Ib)

  提供了（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，其组成和用途。具有化学式（Ia）或（Ib）的化合物作为（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，以及包含本文提供的化合物的药物组合物用于治疗或预防中枢神经系统疾病。更具体地，相关疾病包括抑郁症和疼痛。（Ia）（Ib）
• Two new improved approaches to the synthesis of coumarin-based prodrugs
  作者：Ailian Zheng、Wei Wang、Huijuan Zhang、Binghe Wang

  DOI：10.1016/s0040-4020(99)00121-0

  日期：1999.4

  Our laboratory has recently reported the development of a coumarin-based, esterase-sensitive prodrug system for the preparation of prodrugs of amines, peptides, and peptidomimetics. Biological evaluations including animal studies have demonstrated me clinical potential of this prodrug system. However, the original synthetic method used required a long sequence of reactions with a relatively low overall yield. In this report, we describe two new approaches to the synthesis of these coumarin-based prodrugs. The first approach is a photochemical approach taking advantage of the photoisomerization of cinnamic acid and its derivatives. The second approach is through the catalytic hydrogenation of a triple bond for the generation of me cis double bond in the coumarinic acid moiety. Both approaches allow for the synthesis of these prodrugs in fewer steps with much improved overall yield. (C) 1999 Elsevier Science Ltd. All rights reserved.